Pfizer Inc. (NYSE:PFE – Get Rating) – Stock analysts at SVB Leerink lowered their Q4 2022 earnings estimates for Pfizer in a report issued on Friday, July 29th. SVB Leerink analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $1.35 for the quarter, down from their prior forecast of $1.48. SVB Leerink currently has a “Market Perform” rating and a $53.00 target price on the stock. The consensus estimate for Pfizer’s current full-year earnings is $6.67 per share. SVB Leerink also issued estimates for Pfizer’s Q2 2023 earnings at $1.39 EPS, Q4 2023 earnings at $1.34 EPS, FY2023 earnings at $5.63 EPS and FY2026 earnings at $4.29 EPS.
Several other research analysts have also recently weighed in on PFE. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research note on Tuesday, June 28th. Citigroup boosted their target price on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Morgan Stanley dropped their target price on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research note on Friday, July 8th. Finally, The Goldman Sachs Group set a $50.00 target price on shares of Pfizer in a research note on Friday. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.50.
Pfizer Stock Down 0.4 %
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $27.74 billion for the quarter, compared to analysts’ expectations of $26.20 billion. During the same period in the previous year, the company earned $1.07 earnings per share. The firm’s revenue for the quarter was up 46.8% compared to the same quarter last year.
Institutional Investors Weigh In On Pfizer
A number of large investors have recently modified their holdings of PFE. Bank OZK lifted its position in Pfizer by 0.3% during the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock valued at $4,067,000 after acquiring an additional 195 shares during the period. Hamilton Point Investment Advisors LLC lifted its position in Pfizer by 3.9% during the 2nd quarter. Hamilton Point Investment Advisors LLC now owns 5,279 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 196 shares during the period. Piscataqua Savings Bank raised its holdings in Pfizer by 0.8% in the second quarter. Piscataqua Savings Bank now owns 25,820 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 197 shares during the last quarter. Winfield Associates Inc. raised its holdings in Pfizer by 0.9% in the fourth quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock worth $1,273,000 after buying an additional 200 shares during the last quarter. Finally, Birinyi Associates Inc. raised its holdings in Pfizer by 3.4% in the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 200 shares during the last quarter. Institutional investors own 66.50% of the company’s stock.
In other news, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares of the company’s stock, valued at approximately $760,732. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares of the company’s stock, valued at approximately $760,732. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,126 shares of company stock valued at $2,075,003. Corporate insiders own 0.05% of the company’s stock.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be paid a $0.40 dividend. The ex-dividend date is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.17%. Pfizer’s dividend payout ratio (DPR) is 36.70%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.